lung cancer

New Cigna program aims to ‘unlock’ the value of healthcare dataCigna publication project takes a page out of the big pharma and medical technology playbook.
New universal companion diagnostic paves the way for precision oncologyFDA approves new diagnostic test for non-small cell lung cancer.
How precision medicine is improving patient lives: Real examplesAn expert at the Precision Medicine World Conference shared cancer patient perspectives on the importance of immuno-oncology and breakthrough targeted therapies and how they have extended their lives.
Lung cancer drug approvedSoon after FDA granted accelerated approval for atezolizumab (Tecentriq, Genentech) to treat bladder cancer, the agency okayed the drug to treat metastatic non-small cell lung cancer (NSCLC).
Genetic tests guide cancer therapy, improve efficacyAt the ASCO 2016 Annual Meeting, an expert from the Moffitt Cancer Center will discuss use of genetics to guide targeted-therapies and immunotherapies.
New discoveries, treatments help cancer patients live longer, fuller livesExperts say that value-based medicine is a main theme in cancer care today, and that applies to more than the cost of care.
FDA approves new indication for GilotrifFDA recently approved a new indication for afatinib (Gilotrif, Boehringer Ingelheim) for patients with squamous cell carcinoma of the lung. The once-daily tablets are now indicated for the treatment of patients with the lung cancer, whose disease has progressed after treatment with platinum-based chemotherapy. Here are the top 6 facts to know about Gilotrif.
FDA expands drug to treat NSCLCFDA has extended approval of crizotinib (Xalkori, Pfizer) for the treatment of certain patients with non-small cell lung cancer (NSCLC).
Drug spending rising at slower pacePBM Express Scripts shares findings from its new Drug Trend Report.
Keytruda approved as first-line melanoma treatmentSales of Merck’s Keytruda (pembrolizumab) are expected to increase, after FDA approved the drug for first-line treatment of melanoma.